Jason Napadano wrote about Elto back in 2015: h
Post# of 30027
(Total Views: 538)
Posted On: 06/14/2018 12:17:48 AM
Jason Napadano wrote about Elto back in 2015:
https://finance.yahoo.com/news/ambs-deep-look...00972.html
"We believe with strong Phase 2b data, Amarantus can partner eltoprazine for $30 to $50 million upfront and $300 to $400 million in total potential. We are using the May 2009 transaction between Acadia Pharma and Biovail for pimavanserin ($30 million upfront + $365 million total potential) as the key basis for what a deal might look like...... We arrive at a fair-value assumption for eltoprazine today of approximately $45 million USD. We believe this number could triple in value if the Phase 2b trial is successful. Our $45 million fair value calculation today assumes no contribution from eltoprazine in adult ADHD."
This was assuming the cost would be $15,000 per year per patient, but we now know Gocovri is priced at $28,000 per year. Of course we don't have phase 2 data complete yet, so were certainly not getting $30 million up front, but hopefully with any luck, they can put some half decent deal together.
https://finance.yahoo.com/news/ambs-deep-look...00972.html
"We believe with strong Phase 2b data, Amarantus can partner eltoprazine for $30 to $50 million upfront and $300 to $400 million in total potential. We are using the May 2009 transaction between Acadia Pharma and Biovail for pimavanserin ($30 million upfront + $365 million total potential) as the key basis for what a deal might look like...... We arrive at a fair-value assumption for eltoprazine today of approximately $45 million USD. We believe this number could triple in value if the Phase 2b trial is successful. Our $45 million fair value calculation today assumes no contribution from eltoprazine in adult ADHD."
This was assuming the cost would be $15,000 per year per patient, but we now know Gocovri is priced at $28,000 per year. Of course we don't have phase 2 data complete yet, so were certainly not getting $30 million up front, but hopefully with any luck, they can put some half decent deal together.
(2)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼